Immunic, INC Form 4 insider transactions

IMMUNIC, Inc. Director Tamar D. Howson was granted 150,000 stock options with an exercise price of $0.7729, vesting monthly over one year.

IMMUNIC, Inc. Director Simona Skerjanec was granted 150,000 stock options with an exercise price of $0.7729, vesting monthly over one year.

IMMUNIC, Inc. Director Richard Alan Rudick was granted 150,000 stock options with an exercise price of $0.7729, vesting monthly over one year.

IMMUNIC, Inc. Director Monika Maria Toernsen was granted 150,000 stock options with an exercise price of $0.7729, vesting monthly over one year.

IMMUNIC, INC.'s President and COO, Jason Tardio, has acquired 12,512 shares of common stock and received a grant of 595,000 stock options, signaling increased insider ownership and confidence.

IMMUNIC, INC. Director Joerg Neermann was granted 150,000 stock options with an exercise price of $0.7729, vesting monthly over one year.

IMMUNIC, INC.'s Chief Financial Officer, Glenn Whaley, was granted 503,000 stock options with a vesting schedule over four years, as reported in a recent SEC Form 4 filing.

Immunic, Inc. Director Barclay A. Phillips was granted 150,000 stock options with an exercise price of $0.7729, vesting monthly over one year.

IMMUNIC, Inc. CEO and Director Daniel Vitt has increased his beneficial ownership in the company through a direct purchase of common stock and the acquisition of substantial stock options.

IMMUNIC, INC. Director Joerg Neermann has reported the acquisition of 100,000 shares of common stock over two days in early June 2025, signaling increased insider confidence.

IMMUNIC, INC.'s Chief Financial Officer, Glenn Whaley, has significantly increased his direct beneficial ownership of common stock through two recent acquisitions, including an Employee Stock Purchase Plan transaction and an open market purchase.

IMMUNIC, Inc. Director Richard Alan Rudick has acquired 143,075 shares of common stock, increasing his beneficial ownership to 230,375 shares.

Executive Chairman of Immunic Inc., Duane Nash, files an amendment to a previous Form 4 to correct the vesting schedule of a stock option grant.

Immunic Inc.'s Executive Chairman, Duane Nash, has acquired 300,000 stock options, as reported in a recent SEC filing.

Immunic Inc.'s Chief Medical Officer, Andreas Muehler, was granted stock options for 315,000 shares on December 4, 2024.

Immunic Inc.'s President and COO, Jason Tardio, was granted stock options for 157,500 shares on December 4, 2024.

Immunic's CEO and Director, Daniel Vitt, has acquired 820,000 stock options with a $1.25 exercise price, vesting over 4 years.

Immunic Inc.'s Chief Financial Officer, Glenn Whaley, has acquired 265,000 stock options, according to a recent SEC filing.

Director Richard Rudick purchased 87,300 shares of Immunic Inc. common stock at a price of $1.1497 per share on November 12, 2024.

Director Simona Skerjanec received stock options to purchase up to 150,000 shares of Immunic, Inc.'s common stock as an inducement grant related to her directorship appointment.

Jason Tardio, President and COO of Immunic, Inc., was granted 500,000 stock options on July 12, 2024, according to a Form 4 filing with the SEC.

Director Joerg Neermann acquired 100,000 stock options in Immunic, Inc. on June 11, 2024.

Director Barclay A. Phillips acquired stock options in Immunic, Inc. on June 11, 2024.

Director Richard Alan Rudick reports acquisition of 100,000 stock options in Immunic, Inc.

Director Monika Maria Toernsen reports acquisition of 100,000 stock options in Immunic, Inc.

Director Tamar Howson acquired 100,000 stock options in Immunic, Inc. on June 11, 2024, vesting monthly over one year.

Director Tamar Howson reports the repricing of stock options at Immunic, Inc. following stockholder approval.

Duane Nash, Executive Chairman of Immunic Inc., reports the repricing of employee stock options to $1.72 per share following stockholder approval.

Director Barclay A. Phillips reports repricing of stock options at Immunic, Inc. following stockholder approval.

Immunic Inc.'s CEO, Daniel Vitt, reports the repricing of employee stock options following stockholder approval, adjusting the exercise price to $1.72 per share.